[O-31] Oral Session 31
Clinical trial and Regenerative medicine 1 E

[O-31-1] Long-term Safety and Efficacy of Patisiran in the Global Open-label Extension Study: 24-Month Data

^○Mitsuharu Ueda¹, David Adams², Alejandra González-duarte³, Elizabeth A Mauricio⁴, Thomas H Brannagan⁵, Teresa Coelho⁶, Jonas Wixner⁷, Hartmut Schmidt⁸, Erhan Berber⁹, Marianne Sweetser⁹, Matthew T White⁹, Jing Jing Wang⁹, Michael Polydefkis¹⁰ (1.Department of Neurology, Kumamoto University Hospital, Japan, 2.National Reference Center for FAP (NNERF)/ APHP/ INSERM U 1195/ CHU Bicêtre, Le Kremlin Bicêtre, France, 3.Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, 4.Mayo Clinic, Jacksonville, FL, USA, 5.Department of Neurology, Columbia University, New York City, NY, USA, 6.Centro Hospitalar Universitário do Porto, Portugal, 7.Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, 8.University Hospital Muenster, Muenster, Germany, 9.Alnylam Pharmaceuticals, Cambridge, USA, 10.Johns Hopkins University, Baltimore, USA)